UB Paderborn / Katalog / Suche / in CDI

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

The lancet oncology, 2014-05, Vol.15 (6), p.620-630

2014

Volltextzugriff (PDF)

Ipilimumab-induced colitis: experience from a tertiary referral center

Therapeutic advances in gastroenterology, 2016-07, Vol.9 (4), p.457-462

2016

Volltextzugriff (PDF)

Complications of bone metastases from malignant melanoma

Journal of bone oncology, 2017-09, Vol.8 (C), p.13-17

2017

Volltextzugriff (PDF)

Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels

Journal of clinical oncology, 2001-10, Vol.19 (20), p.4054-4057

2001

Volltextzugriff (PDF)

Patterns of Expression of DNA Repair Genes and Relapse From Melanoma

Clinical cancer research, 2010-11, Vol.16 (21), p.5211-5221

2010

Volltextzugriff (PDF)

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1397-1410

2017

Volltextzugriff (PDF)

Real-world experience of combined ipilimumab and nivolumab for advanced melanoma in a single UK institution

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018-09, Vol.30, p.e2-e2

2018

Volltextzugriff (PDF)

Diffuse cutaneous melanosis is an under-recognized sign with a poor prognosis in patients with melanoma

Clinical and experimental dermatology, 2023-03, Vol.48 (4), p.376-379

2023

Volltextzugriff (PDF)

Improvement in survival for melanoma patients with brain metastases treated with stereotactic radiosurgery and immunotherapy

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018-09, Vol.30, p.e2-e2

2018

Volltextzugriff (PDF)

Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis

European journal of endocrinology, 2022-01, Vol.186 (1), p.83

2022

Volltextzugriff (PDF)

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata

British journal of cancer, 2023-10, Vol.129 (9), p.1490-1499

2023

Volltextzugriff (PDF)

Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study

Annals of surgical oncology, 2018-10, Vol.25 (11), p.3341-3349

2018

Volltextzugriff (PDF)

Real-world experience of Olaratumab and Doxorubicin versus Doxorubicin alone for advanced soft-tissue sarcoma in a UK centre

Clinical oncology (Royal College of Radiologists (Great Britain)), 2019-10, Vol.31, p.e9-e9

2019

Volltextzugriff (PDF)

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Melanoma research, 2015-10, Vol.25 (5), p.432-442

2015

Volltextzugriff (PDF)

Pneumocystis jirovecii pneumonia in a patient with melanoma treated with infliximab and corticosteroids for ipilimumab-associated colitis

Global Dermatology, 2016, Vol.3 (6)

2016

Volltextzugriff (PDF)

MON-290 Ipilimumab Immune-Related ACTH Deficiency Is of Acute Onset and Severe

Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1)

2020

Volltextzugriff (PDF)

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9501-9501

2017

Volltextzugriff (PDF)

Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?

Cancer investigation, 2015-09, Vol.33 (8), p.347-353

2015

Volltextzugriff (PDF)

Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy

Molecular and clinical oncology, 2020-12, Vol.13 (6), p.1-1

2020

Volltextzugriff (PDF)

A Cancer Research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8523-8523

2012

Volltextzugriff (PDF)

NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS -mutant cutaneous melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS9102-TPS9102

2014

Volltextzugriff (PDF)

Adult Cancers in Adolescents and Young Adults

Progress in tumor research, 2016-01, Vol.43, p.64-73

2016

Volltextzugriff (PDF)

D-dimers as a tumor marker in GIST: Can it reduce the frequency of CT scanning in patients receiving palliative imatinib?

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.119-119

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

Ipilimumab-induced colitis: experience from a tertiary referral center

Complications of bone metastases from malignant melanoma

Use of CA-125 to Define Progression of Ovarian Cancer in Patients With Persistently Elevated Levels

Patterns of Expression of DNA Repair Genes and Relapse From Melanoma

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

Real-world experience of combined ipilimumab and nivolumab for advanced melanoma in a single UK institution

Diffuse cutaneous melanosis is an under-recognized sign with a poor prognosis in patients with melanoma

Improvement in survival for melanoma patients with brain metastases treated with stereotactic radiosurgery and immunotherapy

Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata

Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study

Real-world experience of Olaratumab and Doxorubicin versus Doxorubicin alone for advanced soft-tissue sarcoma in a UK centre

Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients

Pneumocystis jirovecii pneumonia in a patient with melanoma treated with infliximab and corticosteroids for ipilimumab-associated colitis

MON-290 Ipilimumab Immune-Related ACTH Deficiency Is of Acute Onset and Severe

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial

Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?

Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy

A Cancer Research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM)

NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS -mutant cutaneous melanoma

Adult Cancers in Adolescents and Young Adults

D-dimers as a tumor marker in GIST: Can it reduce the frequency of CT scanning in patients receiving palliative imatinib?

Suchergebnisse filtern